Biolumpivaxin: Bharat Biotech's New Vaccine Against Lumpy Skin Disease
Source: dairynews.today
Bharat Biotech introduces Biolumpivaxin, a novel vaccine for controlling Lumpy Skin Disease in livestock across India.
Bharat Biotech has unveiled Biolumpivaxin, a groundbreaking vaccine designed to battle the Lumpy Skin Disease (LSD) epidemic plaguing dairy cattle and buffaloes. Launched during the Livestock Prosperity Conclave in Vijayawada, the vaccine is packaged in multi-dose vials, each containing between 25 and 100 doses, and remains stable at a storage temperature of 2-8°C.
Chief Minister of Andhra Pradesh, N. Chandrababu Naidu, inaugurated the launch, underscoring the vaccine's potential to enhance the state's livestock growth by 20% while securing the dairy sector's future. Notably, Biolumpivaxin becomes the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine. It utilizes the LSD virus/Ranchi/2019 strain, collaboratively developed by ICAR-NRCE and Biovet.
The single-dose vaccine regimen, administered annually to cattle and buffaloes, is set to transform disease surveillance practices by distinguishing vaccinated from naturally infected animals. The Indian animal husbandry ministry reports two prior major LSD outbreaks since 2019, resulting in the death of approximately 200,000 cattle and significant milk production losses.
With a production capacity for 500 million doses at its Bengaluru facility, Biovet aims to provide sustainable vaccine supplies to combat this issue. Biovet founder and Bharat Biotech executive chairman, Krishna Ella, emphasized the critical nature of protecting the livestock sector for the country’s economic and social well-being.
The introduction of Biolumpivaxin signifies a substantial move towards the Atmanirbhar Bharat vision, supporting India’s self-reliance in combating agricultural challenges.
Chief Minister of Andhra Pradesh, N. Chandrababu Naidu, inaugurated the launch, underscoring the vaccine's potential to enhance the state's livestock growth by 20% while securing the dairy sector's future. Notably, Biolumpivaxin becomes the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine. It utilizes the LSD virus/Ranchi/2019 strain, collaboratively developed by ICAR-NRCE and Biovet.
The single-dose vaccine regimen, administered annually to cattle and buffaloes, is set to transform disease surveillance practices by distinguishing vaccinated from naturally infected animals. The Indian animal husbandry ministry reports two prior major LSD outbreaks since 2019, resulting in the death of approximately 200,000 cattle and significant milk production losses.
With a production capacity for 500 million doses at its Bengaluru facility, Biovet aims to provide sustainable vaccine supplies to combat this issue. Biovet founder and Bharat Biotech executive chairman, Krishna Ella, emphasized the critical nature of protecting the livestock sector for the country’s economic and social well-being.
The introduction of Biolumpivaxin signifies a substantial move towards the Atmanirbhar Bharat vision, supporting India’s self-reliance in combating agricultural challenges.
